EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

Hyun Chang,1,2,* Jisu Oh,1,3,* Xianglan Zhang,4 Yu Jung Kim,1 Jae Ho Lee,1 Choon-Taek Lee,1 Jin-haeng Chung,5 Jong-Seok Lee1 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, 2Division of Medical Oncology, Departme...

Full description

Bibliographic Details
Main Authors:	Chang H, Oh J, Zhang X, Kim YJ, Lee JH, Lee CT, Chung JH, Lee JS
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-08-01
Series:	OncoTargets and Therapy
Subjects:	epidermal growth factor receptor tyrosine kinase inhibitor squamous cell carcinoma Lung intracellular domain PTEN
Online Access:	https://www.dovepress.com/egfr-protein-expression-using-a-specific-intracellular-domain-antibody-peer-reviewed-article-OTT

Similar Items

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR‐mutated lung adenocarcinoma: a report of two cases
by: Hironori Uruga, et al.
Published: (2020-03-01)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI ) rechallenge in small cell transformation after EGFR-TKI failure: a case report
by: Lee S, et al.
Published: (2018-07-01)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
by: Zhou S, et al.
Published: (2019-10-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
by: Rui Jin, et al.
Published: (2021-06-01)

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
by: Carlo Buonerba, et al.
Published: (2019-08-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
by: Rintu Thomas, et al.
Published: (2019-05-01)

The Relationship between EGFR Mutations and Response and Prognosis of Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
by: Xuebing LI, et al.
Published: (2008-04-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
by: Lu YY, et al.
Published: (2016-03-01)

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study
by: Qing Chang, et al.
Published: (2021-04-01)

GGTI-298 in Combination with EGFR Inhibitors: Evaluating a Novel Therapy in Head and Neck Squamous Cell Carcinomas
by: Zahr, Stephanie
Published: (2013)

GGTI-298 in Combination with EGFR Inhibitors: Evaluating a Novel Therapy in Head and Neck Squamous Cell Carcinomas
by: Zahr, Stephanie
Published: (2013)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations
by: Wenxing DU, et al.
Published: (2019-09-01)

Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer
by: Chang CY, et al.
Published: (2021-09-01)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021-09-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors
by: Wenqiu ZHANG, et al.
Published: (2017-10-01)

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
by: Chunhua Ma, et al.
Published: (2020-03-01)

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
by: Peng L, et al.
Published: (2017-08-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR
by: Baldacci, Simon
Published: (2017)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
by: K. K. Laktionov, et al.
Published: (2019-06-01)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
by: Sho Watanabe, et al.
Published: (2021-03-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma
by: Manoj Kumar Kashyap, et al.
Published: (2018-02-01)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
by: Thitinan Aiebchun, et al.
Published: (2021-04-01)

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
by: He ZY, et al.
Published: (2019-03-01)

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy
by: Panpan Lv, et al.
Published: (2020-01-01)

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors
by: Xiuqin Hu, et al.
Published: (2017-11-01)

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
by: Chang CY, et al.
Published: (2021-03-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations
by: Qunhui WANG, et al.
Published: (2016-08-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)